Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10474572 | 0.84 | TYMP (0.42) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL22047282 | 0.83 | CYP1A2 (0.41) | TK1TYMPALDH1A1BLMSMN1; SMN2 | |
| SCHEMBL17899463 | 0.83 | SMN1; SMN2 (0.55) | HPGDALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL15948684 | 0.80 | TYMP (0.42) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL22398916 | 0.80 | MAPK1 (0.44) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL16038197 | 0.79 | TYMP (0.60) | MAPK1HPGDTK1TYMP | |
| SCHEMBL22381003 | 0.78 | ALDH1A1 (0.43) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL6153438 | 0.78 | MAPK1 (0.42) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL19662195 | 0.77 | ALDH1A1 (0.42) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL12646693 | 0.76 | SMN1; SMN2 (0.40) | MAPK1HPGDTK1TYMPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130194-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | HORIZON TECHNOLOGY FINANCE CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-29 | — | — | US | disclosed |
| US-20210381040-A1 | METHODS FOR CHEMICAL LIGATION OF NUCLEIC ACIDS | ILLUMINA, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-18 | — | — | US | disclosed |
| US-10363266-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | Neurovision Pharma GmbH (DE) | 2019-07-30 | — | — | US | disclosed |
| US-9701962-B2 | Hydrophobically modified antisense oligonucleotides comprising a ketal group | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-07-11 | — | — | US | disclosed |
| US-8183355-B2 | Method for the synthesis of oligonucleotide derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-05-22 | — | — | US | disclosed |
| US-20110245478-A1 | Method for the Synthesis of Oligonucleotide Derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2011-10-06 | — | — | US | disclosed |
| US-20110082288-A1 | PURIFICATION OF SYNTHETIC OLIGOMERS | MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | MAPK1 4496/4885HPGD 4570/4885TK1 474/4885 |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLL, POLQ, POLB | MAPK1 3556/4885HPGD 522/4885TK1 54/4885 |
| US-20110082288-A1 | PURIFICATION OF SYNTHETIC OLIGOMERS | RNGTT, NOP2, CAPZA2 | MAPK1 4672/4885HPGD 3815/4885TK1 1545/4885 |
| US-20110245478-A1 | Method for the Synthesis of Oligonucleotide Derivatives | MSN, RNGTT, DCLRE1B | MAPK1 3443/4885HPGD 4318/4885TK1 56/4885 |
| US-10363266-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | TGFBR1, TGFBR2, TGFB1 | MAPK1 181/4885HPGD 4222/4885TK1 89/4885 |
| US-20230130194-A1 | TRANSGLUTAMINASE-MEDIATED CONJUGATION | TGM2, TGM3, TGM1 | MAPK1 4783/4885HPGD 2300/4885TK1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.